Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)

Sponsor
Beijing Sanbo Brain Hospital
Study ID
NCT04952571
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab and Bevacizumab — DRUG
    Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total. Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion.

Study Details

This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.

Key Dates

Start date
Jun 27, 2021
Status verified
Oct 2024
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022

Study Design

Enrollment
3 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: GBM at first relapse
  • Experimental: GBM at second relapse

Primary Outcome Measure

Progression-free survival rate at 6 months [ Time Frame: Up to three years ]

Related Studies